Wheels Launches Operations In Malta Backed By Local Partner

Marking its first EU expansion post-acquisition, Wheels set to roll out a fleet of 600 vehicles reinforcing its commitment to sustainable urban mobility. Wheels, a subsidiary of micromobility.com Inc.

Marking its first EU expansion post-acquisition, Wheels set to roll out a fleet of 600 vehicles reinforcing its commitment to sustainable urban mobility.

Wheels, a subsidiary of micromobility.com Inc. (NASDAQ:MCOM), pioneering global micromobility ecosystem, today is proud to announce its expansion into Malta, marking its first post-acquisition expansion in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230620261593/en/

Visit www.micromobility.com

Commencing service on June 26, Wheels has been granted the license to operate in Malta, deploying a fleet of 600 vehicles. This operation will be carried out in collaboration with a seasoned local partner, demonstrating proven expertise in the industry and its logistics.

Salvatore Palella, CEO and Founder of micromobility.com Inc., commented, “Our entrance into Malta signifies an exciting new chapter in Wheels’ journey. This expansion underscores our commitment to reinventing urban mobility on a global scale. We are thankful for the opportunity to bring our eco-friendly transportation solutions to the residents and visitors of Malta. We look forward to a successful partnership with our local collaborators and delivering exceptional service to the Maltese community.”

This move marks a historic moment for Wheels, signifying the brand’s continued EU expansion. The company’s footprint in Malta will solidify its position as a pioneer in the micromobility industry, setting the stage for future growth and sustainability initiatives in Europe.

Total
0
Shares
Related Posts
Read More

Takeda Announces Late-Breaking Data From Phase 2b Study Of TAK-279, An Investigational, Oral, Once-Daily TYK2 Inhibitor, In Patients With Active Psoriatic Arthritis At American College Of Rheumatology Convergence Annual Meeting

− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30 mg Respectively) Achieving At Least an ACR 20 Response Compared to 29.2% in the Placebo Group at Week 12 (p =

TAK